Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999–2011
| Autor: | Bonnie Dean, Frank J. Palella, John Hammer, Doug Ward, Rachel Hart, John T. Brooks, Benjamin Young, Kathleen C. Wood, Marcus D. Durham, Jerian Denise Dixon-Evans, Dania Beadle, Dana Franklin, Bienvenido G. Yangco, Richard M. Novak, Kate Buchacz, Jane Esteves, Conor Daniel Flaherty, Ellen Tedaldi, Jack Fuhrer, Cheryl Stewart, Faye Ruley, Ramona A. Christian, Thilakavathy Subramanian, Mia Scott, Kenneth S. Greenberg, Princess Graham, Darlene Hankerson, Linda Ording-Bauer, Kalliope Chagaris, Rita Kelly, Kenneth A. Lichtenstein, Rosa Franklin, Andrea Wendrow, Carl Armon, Renata Smith, Barbara Widick, Joan S. Chmiel, Saira Jahangir, Harlen Hays |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Genotyping Techniques Human immunodeficiency virus (HIV) HIV Infections Microbial Sensitivity Tests Drug resistance medicine.disease_cause ANTIRETROVIRAL AGENTS Internal medicine Drug Resistance Viral Outpatients Epidemiology Genotype Antiretroviral naive medicine Humans Pharmacology (medical) Longitudinal Studies Prospective Studies Temporal change Aged Pharmacology business.industry HIV Middle Aged United States Infectious Diseases Immunology Genotypic resistance Female business |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 70:2337-2346 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dkv120 |
| Popis: | BackgroundMonitoring antiretroviral drug resistance can inform treatment recommendations; however, there are few such data from US patients before they initiate ART.MethodsWe analysed data from HIV Outpatient Study (HOPS) participants from nine US HIV clinics who were diagnosed with HIV infection during 1999–2011. Using the IAS-USA December 2010 guidelines, we assessed the frequency of major drug resistance mutations (mDRMs) related to antiretroviral agents in viral isolates from patients who underwent commercial genotypic testing (GT) for resistance before initiating ART. We employed general linear regression models to assess factors associated with having undergone GT, and then factors associated with having mDRM.ResultsAmong 1531 eligible patients, 758 (49.5%) underwent GT before first ART, increasing from 15.5% in 1999–2002 to 75.9% in 2009–11 (P 5.0 log10 copies/mL and those with a first HOPS visit in 2006 or later were significantly (P ConclusionsDuring 1999–2011, GT use among antiretroviral-naive patients became more common, but a quarter of patients in recent years remained untested. The frequency of mDRMs remained stable over time at about 15%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|